Cheviot Value Management LLC Reduces Position in Medtronic PLC $MDT

Cheviot Value Management LLC lessened its holdings in shares of Medtronic PLC (NYSE:MDT) by 90.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 9,427 shares of the medical technology company’s stock after selling 88,892 shares during the period. Cheviot Value Management LLC’s holdings in Medtronic were worth $950,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Corundum Trust Company INC purchased a new stake in shares of Medtronic during the third quarter valued at $27,000. Lodestone Wealth Management LLC purchased a new position in Medtronic in the 4th quarter worth about $27,000. Anfield Capital Management LLC lifted its holdings in Medtronic by 410.7% during the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after buying an additional 230 shares in the last quarter. Valley Wealth Managers Inc. bought a new stake in Medtronic during the 3rd quarter valued at about $29,000. Finally, Board of the Pension Protection Fund purchased a new stake in Medtronic in the 4th quarter valued at about $29,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Barclays increased their price objective on Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. UBS Group decreased their target price on Medtronic from $104.00 to $90.00 and set a “neutral” rating for the company in a research report on Wednesday, April 22nd. Needham & Company LLC reiterated a “buy” rating and issued a $120.00 target price on shares of Medtronic in a report on Thursday, March 26th. Wells Fargo & Company assumed coverage on Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 price target on the stock. Finally, Citigroup cut their price target on Medtronic from $117.00 to $110.00 and set a “buy” rating on the stock in a research note on Tuesday, April 7th. Fifteen research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $107.80.

Medtronic Trading Down 2.5%

Shares of NYSE:MDT opened at $76.03 on Friday. The business’s 50-day moving average is $87.26 and its 200 day moving average is $94.43. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.54 and a quick ratio of 1.87. Medtronic PLC has a 1 year low of $75.91 and a 1 year high of $106.33. The firm has a market capitalization of $97.62 billion, a P/E ratio of 21.18, a P/E/G ratio of 1.85 and a beta of 0.62.

Medtronic (NYSE:MDT) last issued its quarterly earnings results on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.34 by $0.02. Medtronic had a return on equity of 14.82% and a net margin of 13.00%.The business had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter last year, the company earned $1.38 earnings per share. The company’s quarterly revenue was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, research analysts predict that Medtronic PLC will post 5.57 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, April 17th. Investors of record on Friday, March 27th were paid a $0.71 dividend. The ex-dividend date was Friday, March 27th. This represents a $2.84 dividend on an annualized basis and a yield of 3.7%. Medtronic’s dividend payout ratio (DPR) is 79.11%.

Insiders Place Their Bets

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the company’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the transaction, the executive vice president owned 32,768 shares in the company, valued at approximately $3,201,761.28. This represents a 61.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.26% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received the CE Mark for its Stealth AXiS system, adding to the earlier FDA approval and expanding the next-generation planning, navigation, and robotics platform into Europe. That strengthens the company’s surgical robotics and imaging portfolio and could support future procedure growth. Following FDA Approval, Medtronic (MDT) Receives CE Mark For Stealth AXiS System
• Positive Sentiment: Medtronic expanded its neuromodulation business by launching Adaptive Deep Brain Stimulation for Parkinson’s disease in India, which broadens its reach in a large and growing market and highlights continued innovation in its neurological therapies segment. Medtronic Expands Neuromodulation Reach With Adaptive DBS Launch In India
• Neutral Sentiment: Several articles focused on whether MDT looks attractive after recent share-price weakness and whether Wall Street’s bullish analyst views make the stock worth buying. These pieces can keep attention on the name, but they did not add new fundamental data. Is Medtronic (MDT) Offering Value After Recent Share Price Weakness? Is It Worth Investing in Medtronic (MDT) Based on Wall Street’s Bullish Views?
• Neutral Sentiment: Third-party “best stocks” and retiree-income articles also mentioned Medtronic, which may provide some investor visibility, but these are largely promotional and not direct company-specific catalysts. 3 Healthcare Stocks Every Retiree Should Consider Better Than Intuitive Surgical? 1 Under-the-Radar Healthcare Stock to Buy and Hold Forever

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).